Answers are grounded in this paper and cite their sources.
Several different mechanisms can contribute to drug resistance to anti-HER2 treatment in GEA, mainly through loss of or mutations in the HER2 receptor and upregulation of alternative receptors such as MET, HER3, and FGFRs. Despite these preclinical results, methods to overcome the proposed resistance mechanisms in the clinical setting are lacking. Therefore, further investigation of therapy resistance in GEA patients treated with HER2 targeted therapy is essential to overcome resistance and improve treatment outcome of these patients.
No takes yet. Share an insight, caveat, or question.
Blangé et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: